All is once again quiet on the US-Iran war front, and some kind of dialogue to resolve the issues between the two seems to be still underwa...

It is quite likely that the news cycle this and the next week will be about the direction of US interest rates and yield. If that turns out...

Goods left the warehouse. The invoice went out. So it must be a sale, right? Not always. Under the rules, a sale counts only when the custo...

As the old saying goes: Nothing can be ruled out on the street. Which means that one should be prepared for anything. Now, what is the prob...

When business updates start to come in or when some FMCG or auto companies indicate that things are not all good in the rural space, we may...

From a macro perspective, it is clearly a good time to be bullish. But as valuations remain high in parts of the market despite the recent ...

As the market seems to be in comeback mode, it helps to be aware that the best (and probably biggest) wealth creator of the last couple of ...

We are in a phase in the US-Israel-Iran war where statements are made, then retracted. And, in a matter of just 48 hours, they are made all...

There are market phases when one risk dominates. Then there are phases like this, when risks arrive from every direction and refuse to stan...

India's anti-obesity drug market sees a slowdown after initial generic semaglutide sales. Demand has eased from its peak, with growth moder...

Even in normal times it is futile to try and guess the outcome of most global events. But in the New World Order, it makes no sense at all ...

Ray Kroc, the man behind McDonald's global success, believed in tailoring pitches. He compared sales to baseball, stating no two clients ar...

For the last few earnings seasons, the message has been: “Show me growth, I have the money.” Stocks with better-than-expected earnings saw ...

This partnership aims to accelerate Rosada's expansion and solidify its presence in the premium children's market. The investment will fuel...

After the correction, the street will reach a stage where, if a company delivers numbers, there will be enough money waiting to move into t...

There was a time when the Indian pharma story in the US was almost entirely about inspection risk. The US FDA would inspect a plant, a warn...

Cipla is charting its next growth phase with a strong focus on innovation, complex generics, and biosimilars. The company plans significant...